The UK and US have signed a landmark bilateral deal that will preserve no levies on UK pharmaceutical products entering the American market.
Agreement Details of the Deal
As part of the deal, the UK has agreed to raise spending on drugs through the public health system. This commitment ensures that duties on these key exports will stay at zero for a duration of the next three years.
This development follows recent statements to dramatically increase tariffs on patented pharmaceutical products, with potential rates mentioned up to double the cost.
"This deal between the UK reinforces the international landscape for innovative medicines and introduces long-overdue equity to American-British medicine commerce," an announcement said.
Commercial Significance
Drugs constitute one of the UK's most significant goods shipped to the United States, which is by far the biggest buyer for large companies like GSK and AstraZeneca.
Trade data reveal that in the one-year period to the end of September, the UK sold pharmaceutical products totaling £11.1bn to the US. This amount accounted for a significant portion of British export trade in that timeframe.
"This agreement secures employment, stimulates investment and sets the stage for the UK to become a global hub for medical research," a government official stated.
Key British Pledges
The pact involves several specific changes from the United Kingdom:
- Revised Affordability Limit: The UK will lift the affordability limit at which it deems new therapies to be prohibitively costly by a quarter.
- Boosted Medicine Funding: There is a aim to double total public funding on treatments from 0.3% of GDP to 0.6 percent over the coming ten years.
- Payback Limit: The percentage drug companies must return to the NHS to stay within budget will be capped at fifteen percent. In the past, repayments topped twenty percent.
Industry Background
The deal follows a ongoing tension between the sector and the British authorities over medicine costs and approval rates.
This friction were exacerbated by claims that American consumers were paying significantly more for the equivalent treatments than consumers in the UK and Europe.
Recently, several significant manufacturing plans in the UK have been paused or cancelled, while multi-billion-dollar funding commitments have been directed toward US facilities.
A senior figure acknowledged that the NHS needed to spend more on treatments, noting that its expenditure on drugs had declined as a percentage of its resources over the past decade.
